U.S. markets closed

Novartis AG (NVSEF)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
88.75+1.65 (+1.89%)
At close: 9:46AM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close87.10
Bid0.00 x 0
Ask0.00 x 0
Day's Range88.75 - 88.75
52 Week Range77.45 - 97.30
Avg. Volume23,466
Market Cap199.428B
Beta (5Y Monthly)0.51
PE Ratio (TTM)25.50
EPS (TTM)3.48
Earnings DateN/A
Forward Dividend & Yield3.22 (3.63%)
Ex-Dividend DateMar 04, 2021
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Ionis (IONS) Q1 Loss Widens Year Over Year, Sales Miss

    Ionis (IONS) Q1 Loss Widens Year Over Year, Sales Miss

    Ionis (IONS) Q1 adjusted loss per share was wider than the year-ago figure. The company maintains its guidance for 2021.

  • GuruFocus.com

    3 High-Yield Stocks for Dividend Investors

    These businesses are yielding back more than the S&P 500

  • Novartis' Beovu Non-Inferior To Aflibercept In Phase 3 Diabetic Macular Edema Study

    Novartis' Beovu Non-Inferior To Aflibercept In Phase 3 Diabetic Macular Edema Study

    Novartis AG (NYSE: NVS) has reported that its Beovu (brolucizumab) drug met primary endpoints in Phase 3 KESTREL and KITE trials conducted in diabetic macular edema (DME) patients. According to one-year data, 6mg Beovu showed non-inferiority in change in best-corrected visual acuity from baseline compared to 2mg Regeneron Pharmaceuticals Inc's (NASDAQ: REGN) Eylea (aflibercept). In the KESTREL study, patients in the Beovu arm demonstrated a mean of 9.2 letters against 10.5 letters for those on aflibercept. Meanwhile, in the KITE trial, Beovu showed a mean of 10.6 letters compared to 9.4 letters with aflibercept. For secondary endpoints, data revealed intraretinal and subretinal fluid at weeks 32 and 52 in fewer eyes treated with Beovu versus those on aflibercept. The company added that central subfield thickness (CSFT) levels below 280μm were found at weeks 32 and 52 in more eyes treated with Beovu versus eyes treated with aflibercept. Fluid is considered a vital disease activity marker in DME, while CSFT is a crucial fluid marker in the retina. Novartis said that these trial data might enable fewer injections of Beovu. Results showed Beovu was overall well-tolerated in both trials. The most common ocular and non-ocular adverse events reported were conjunctival hemorrhage, nasopharyngitis, and hypertension. Novartis plans to submit these one-year results to regulatory authorities in the first half of this year. Two-year results from KESTREL and KITE are expected to be available later this year. Price Action: NVS shares are up 0.99% at $86.08 in the premarket session on the last check Monday. See more from BenzingaClick here for options trades from BenzingaMesoblast Shares Rise As Remestemcel-L Cuts Mortality In Patients Below 65 Years With COVID-19 Related Respiratory DistressSanofi Shares Rise On Q1 Sales Boosted By Dupixent Franchise; Plans To Restart Haemophilia Study With Fitusiran© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.